MedTrace Logo

A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.

NCT04810676 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2021-06-10

No results posted yet for this study

Summary

A clinical trial to evaluate the pharmacokinetic profiles and safety of CKD-383.

Conditions

  • Type2 Diabetes Mellitus

Interventions

DRUG

CKD-501, D745, D150

QD, PO

DRUG

CKD-383

QD, PO

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Principal Investigators

  • Min-soo Park, MD, PhD. · Severance Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-04-16
Primary Completion
2021-05-20
Completion
2021-05-26

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04810676 on ClinicalTrials.gov